A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer (PDF inhibitor)

IlDong Pharmaceutical

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: IDP-73152 mesylate 40 mg; Drug: IDP-73152 mesylate 160 mg; Drug: Placebo; Drug: IDP-73152 mesylate 1280 mg; Drug: IDP-73152 mesylate 320 mg; Drug: IDP-73152 mesylate 80 mg; Drug: IDP-73152 mesylate 640 mg

Study type: Interventional

Funder types: Industry

Identifiers

NCT01904318

ID-PDF-70-1

Details and patient eligibility

About

A dose block-randomized, double-blinded, placebo-controlled, single dose, dose-escalation clinical phase I study to evaluate the safety, pharmacokinetics and food effect of IDP-73152 mesylate after oral administration in healthy male volunteer

Enrollment: 56 patients

Sex: Male

Ages: 20 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Aged 20-50 years inclusive, at screening visit.
• 55kg ≤ Body weight ≤90kg and body mass index (BMI) between 18.0 - 25.0 kg/m2.
• Subject does not have congenital or chronic disease and is without pathologic symptom or finding on medical exam.
• Subject was determined eligible according to the results of clinical laboratory tests like serum test, hematologic test, blood chemistry test, urine test etc. and vital signs, electrocardiography, physical exam etc. performed during the screening exam.
• Subject decided to participate voluntarily and gave written Informed consent to comply with the instructions after listening to and fully understanding the detailed explanation about this trial.

Exclusion criteria

• Subject has clinically significant liver, kidney, neurologic, immunologic, respiratory, endocrine disease or hematologic•oncologic disease, cardiovascular disease or psychiatric disease (mood disorder, compulsive disorder etc.) or such medical history (including subject with hepatitis virus in case of liver disease).
• Subject has history of gastrointestinal disease (such as Crohn's disease, ulcer, acute or chronic pancreatitis etc.) or gastrointestinal surgery (except simple appendectomy or hernia operation) that can affect the absorption of the study drug.
• Subject has hypersensitivity reaction to drug (aspirin, antibiotics etc.) or history of clinically significant hypersensitivity reaction.
• Specific laboratory values at screening including: AST(SGOT) and/or ALT > 1.25 times the upper limit of normal; QTc > 430 ms or clinical significance of abnormal electrocardiographic patterns.
• Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) < 90 mmHg or > 150 mmHg or diastolic BP (DBP) < 60 mmHg or > 110 mmHg at screening evaluation.
• History of recent tobacco abuse in the past 3 months.
• Subject took any prescribed drug or oriental medicine within 2 weeks prior to the first medication or any over-the-counter (OTC) drug or vitamins within 1 week prior to the first medication (however, the subject can be included if other criteria are met according to the discretion of the investigator).
• Use of an investigational drug or treatment in past 2months
• Subject donated whole blood within 2 months prior to the first medication or apheresis within 1 month prior to the first medication or received blood transfusion within 1 month prior to the first medication.
• Subject continually drinks (in excess of 21 units/week, 1 unit = 10 g of pure alcohol) or cannot abstain from drinking through the study period.
• History of recent tobacco abuse (within 3 months)
• Subject took grapefruit/caffeine-containing food within 3 days prior to the first medication, or cannot abstain from taking during the hospitalization period.
• Subject was judged not to be eligible according to the discretion of the investigator for other reasons.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

56 participants in 7 patient groups, including a placebo group

IDP-73152 mesylate 40 mg

Experimental group

Treatment:

Drug: IDP-73152 mesylate 40 mg

IDP-73152 mesylate 80 mg

Experimental group

Treatment:

Drug: IDP-73152 mesylate 80 mg

IDP-73152 mesylate 160 mg

Experimental group

Treatment:

Drug: IDP-73152 mesylate 160 mg

IDP-73152 mesylate 320 mg

Experimental group

Treatment:

Drug: IDP-73152 mesylate 320 mg

IDP-73152 mesylate 640 mg

Experimental group

Treatment:

Drug: IDP-73152 mesylate 640 mg

IDP-73152 mesylate 1280 mg

Experimental group

Treatment:

Drug: IDP-73152 mesylate 1280 mg

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo